Latest Videos Archives

Evidence-Based Guideline for Management of Priapism: Perspectives from AUA/EAU Guideline Panel

Posted by Trinity J. Bivalacqua, MD, PhD | Jun 2020

Trinity J. Bivalacqua, MD, PhD, Director of Urologic Oncology at Johns Hopkins Medicine, discusses potential solutions to the issues with bacillus Calmette-Guérin (BCG) as a treatment for high-risk non-muscle invasive bladder cancer (NMIBC). Intravesical BCG is more effective than chemotherapy for NMIBC, but approximately ⅓ of high-risk patients are BCG-unresponsive, and there is also a BCG shortage. Dr. Bivalacqua lists potential solutions to both these problems, including early cystectomy, increasing the availability of BCG by using alternative strains, and enhancing immunotherapy. He concludes by discussing research intended to characterize immune cell expression among patients with NMIBC treated with BCG which found that immune checkpoint inhibition with BCG may be beneficial in a subset of patients who experience tumor recurrence after BCG.

Point-Counterpoint: There is a Role for Currently Available Biomarkers/Genomics in the Risk Stratification of Prostate Cancer

Posted by E. David Crawford, MD | Jun 2020

E. David Crawford, MD, Editor-in-Chief of Grand Rounds in Urology, and Alan H. Bryce, MD, Chair of the Division of Hematology and Medical Oncology and Assistant Professor of Medicine at the Mayo Clinic in Phoenix, Arizona, present a Point-Counterpoint on the relative value of genomics and biomarkers in prostate cancer risk stratification. Dr. Crawford, presenting the pro side, argues that doctors need to do biomarker testing to know which patients to biopsy, follow closely, and treat with radiation. Dr. Bryce, presenting the con side, contends that while germline testing is beneficial, other biomarker tests have inconsistent results for prostate cancer patients.

29MHz High Resolution Micro-Ultrasound: Improving Real-Time Targeting of Prostate Biopsies

Posted by Neal D. Shore, MD | Jun 2020

Neal D. Shore, MD, FACS, Medical Director for the Carolina Urologic Research Center and a urologist at the Atlantic Urology Clinics in Myrtle Beach, South Carolina, discusses the use of a 29MHz micro-ultrasound (MUS) in targeting suspicious regions during prostate biopsy. He explains how the MUS can expedite time to diagnosis through improved real-time visualization, notes the short 15-case learning curve of the device, and discusses studies demonstrating improved negative predictive value and sensitivity of MUS compared to MRI.

Creating Balance in Your Personal and Professional Life (Part 1 of 2)

Posted by Neil H. Baum, MD | Jun 2020

Neil H. Baum, MD, Clinical Professor of Urology at Tulane Medical School in New Orleans, Louisiana, discusses how important it is for physicians to create balance in their personal and professional lives. Dr. Baum offers five suggestions for how urologists can do this in order to avoid burnout. He highlights why doctors have such problems balancing life and career and discusses what happens when they are out of balance. The solutions that Dr. Baum offers are: continue learning, be ethical, set priorities, just say no, and make a difference.

Genetic Testing in Prostate Cancer

Posted by Mohammad O. Ramadan, MD | Jun 2020

Mohammad O. Ramadan, MD, discusses the importance of genetic testing for prostate cancer screening, diagnosis, and treatment. He notes that there is currently a professional practice gap in this area, even as genetic testing becomes more widely available. Studies suggest that approximately 17% of prostate cancer patients are biomarker positive, and therefore may benefit more than other patients from treatments like PARP inhibitors. Research like this has led the NCCN to recommend germline genetic testing for all men with high-risk, very-high-risk, regional, or metastatic prostate cancer. With this guideline in place, urologists will have to quickly figure out how to provide widespread testing, and may have to partner with geneticists.